ARTICLE SUMMARY:
electroCore's first plan for its vagus nerve stimulation technology was to to address inflammation and the airway reactivity and bronchoconstriction that occur during asthma as well as anaphylaxis. The company has parlayed that original R&D into an FDA Emergency Use Authorization for use of its device in COVID-19 patients.
On July 13, 2020 the FDA issued an Emergency Use Authorization (EUA) covering the use of electroCore’s noninvasive vagus nerve stimulation device, gammaCore Sapphire CV for the treatment of asthma exacerbation associated with COVID-19. In the hospital, such treatment has the potential to keep patients off of ventilators, or it might keep patients out of the hospital in the first place.
